High performance liquid chromatographic fluorescence detection method for the quantification of rivastigmine in rat plasma and brain: Application to preclinical pharmacokinetic studies in rats

Journal of Young Pharmacists

Volumn 3, Issue 4, 2011, Pages 315-321

  Arumugam, K ^a   Chamallamudi, M R ^a   Mallayasamy, S R ^a   Mullangi, R ^b   Ganesan, S ^a   Jamadar, L ^a   Ranjithkumar, A ^c   Udupa, N ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b JUBILANT BIOSYS LTD   (India)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

HPLC method validation; pharmacokinetics; plasma brain correlation; rivastigmine

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; RIVASTIGMINE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG STRUCTURE; FLOW RATE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; PHASE SEPARATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 82955175566     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.90244     Document Type: Article

References (16)

1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-9. (Pubitemid 12106486)
2. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Ther 2004;26:615-30.
3. Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993;41:31-91. (Pubitemid 23140755)
4. Millard CB, Broomfield CA. Anticholinesterases: Medical applications of neurochemical principles. J Neurochem 1995;64:1909-18.
5. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholin-esterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47. (Pubitemid 28421485)
6. Orhan G, Orhan I, Sener B. Recent developments in natural and synthetic drug research for Alzheimer's Disease. Lett Drug Des Discov 2006;3:268-74. (Pubitemid 43764781)
7. Pommier F, Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B 2003;784:301-13. (Pubitemid 36044013)
8. Frankfort SV, Ouwehand M, van Maanen MJ, Rosing H, Tulner LR, Beijnen JH. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:3330-6. (Pubitemid 44763929)
9. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, Patel M, et al. A rapid and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B 2007;852:115-21. (Pubitemid 46830101)
10. Lee L, Hossain M, Wang Y, Sedek G. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. J Clin Pharmacol 2004;44:599-604. (Pubitemid 38668022)
11. Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet 2002;41:225-34. (Pubitemid 34415840)
12. Enz A, Chappuis A, Dattler A. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed Chromatogr 2004;18:160-6. (Pubitemid 38584833)
13. Sha Y, Deng C, Liu Z, Huang T, Yang B, Duan G. Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples. J Chromatogr B 2004;806:271-6. (Pubitemid 38686516)
14. Karthik A, Subramanian GS, Surulivelrajan M, Ranjithkumar A, Kamat SB. Fluorimetric determination of rivastigmine in rat plasma by a reverse phase-high performance liquid chromatographic method. Application to a pharmacokinetic study. Arzneimittelforschung 2007;57:705-11.
15. Arumugam K, Chamallamudi MR, Gilibili RR, Mullangi R, Ganesan S, Kar SS, et al. Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS. Biomed Chromatogr 2011;25:353-61.
16. US DHHS, FDA, CDER. Guidance for Industry: Bioequivalence Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Veterinary Medicine (CVM), 2006. Available from: http://www/fda.gov/cder/ guidance/index.htm. last cited on 2010 Nov 25.